NMD Pharma Receives Grant from The Innovation Fund Denmark
Grant will be used to develop a ClC-1 Inhibitor as a novel drug to reverse neuromuscular blockade after surgery
NMD Pharma A/S, a biotech company leading in the development of novel therapeutics for neuromuscular disorders, today announces that it has received a grant of 629,000 EUR from The Innovation Fund Denmark to develop a ClC-1 inhibitor as a novel drug to reverse neuromuscular blockade after surgery.
In the majority of surgeries performed under general anesthesia, patients are placed in neuromuscular blockade using pharmacological agents (NMBA) that block neuromuscular transmission. While the use of NMBA enable procedures, they can also cause a delay in recovery from surgery and increase risk of serious post-surgery complications such as respiratory crisis and aspiration-induced pneumonia. To mitigate such risks, IV drugs known as Reversal Agents can be administered at the end of surgery to accelerate and safeguide recovery.
Thomas Holm Pedersen, Chief Executive Officer, commented: “Whilst there are Reversal Agents already on the market, they are often associated with serious risks and adverse events. ClC-1 inhibitors strengthen neuromuscular transmission by blocking inhibitory current at the neuromuscular junction and NMD Pharma has already shown that our ClC-1 inhibitor compounds can reverse all types of NMBA in early animal models. We are very pleased to have received this grant from The Innovation Fund Denmark which will allow us to develop the first Reversal Agent, highly specific for skeletal muscle, that can safely reverse blockade any type of NMBA.”
Contacts
NMD Pharma A/S
Thomas Holm Pedersen, CEO
E-mail: contact@nmdpharma.com
Consilium Strategic Communications
Mary-Jane Elliott / Ashley Tapp / Lindsey Neville
E-mail: NMDPharma@consilium-comms.com
Tel: +44 (0)20 3709 5700
About NMD Pharma
NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in-vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received seed financing from Novo Seeds, Lundbeckfonden Emerge and Capnova in 2016, and in 2018 raised a €38 million Series A financing, led by new investor INKEF Capital, together with new investor Roche Venture Fund and existing investors Novo Seeds and Lundbeckfonden Emerge. Find out more about us online at http://www.nmdpharma.com/.